Mitochon Pharmaceuticals, Inc.

In case you missed my talk a week ago at ALS ONE, they recorded my presentation: https://lnkd.in/eNq-2_ii? The 20 minute talk provides an overview of the pharmacology of MP-101, a mitochondrial specific proton (H+) therapy. I also discuss the preclinical data in ALS showing recovery from paralysis and peak at Multiple Sclerosis. Finally, I discuss the unique clinical design of our ongoing ALS study.?Not enough time to discuss applications to other movement disorders such as DMD, FA, etc., also rooted in mitochondrial disfunction with poor calcium homeostasis.

Mitochon Pharmaceuticals, Inc. is pleased to announce that with the extraordinary work by Dr. Lan Wei-LaPierre’s lab, our ALS paper is fresh off the press today!?MP101, the first ever small molecule providing of “recovery from paralysis” in hSOD1 G93A ALS model. https://lnkd.in/e3VshQYT? #ALS

“Micro-doses of Mitochondrial Uncoupler MP101 in hSOD1 G93A Provides the First Ever Small Molecule with Functional Recovery from Paralysis and Hints that ALS is a Solvable Problem” is the topic of my talk one month from today, at ALS ONE "Industry Day" Nov 14, 11:40 – 12:00pm. Please join me for a Mitochon Pharmaceuticals, Inc., brief overview of both our "disruptive" preclinical work, sALS clinical study ongoing now in Europe, and plans for future studies in USA/Europe. https://lnkd.in/eeQNWQAk #ALS #mitochondria

Oct 5th at SfN will be a good opportunity to meet F2F and discuss our ongoing clinical study in ALS, MS and AD:?“A Phase I/IIa Basket Study to Assess MP101’s Effects on Biomarkers in the Cerebrospinal Fluid of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s and Multiple Sclerosis (MS) Patients”. ?Poster # C67, session PSTR015, Oct. 5 from 1-5pm.?Abstract # 1768 https://lnkd.in/epeyUP_r

Mitochon Pharmaceuticals, Inc.’s hat is off to Dr. Karin Westlund High for her labs work in pioneering new treatments for the most serious neuropathic pain. She provided a impactful presentation of her studies yesterday at MHSRS on the striking effects of oral small molecule, MP201, in alleviating pain in trigeminal neuralgia (TgN) model.?MP201 is a mitochondrial specific protonophore, non-addictive, non-opioid and comes with a completely novel MOA in reducing over excitation due to calcium inside-out of the cell vs. Gabapentin, outside-in. More to come, but a wonderful beginning!

Please stop by my poster “A Phase I/IIa Basket Study to Assess MP101’s Effects on Biomarkers in the Cerebrospinal Fluid of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s and Multiple Sclerosis (MS) Patients”, at Society for Neuroscience. ?Topic will discuss Mitochon Pharmaceuticals, Inc.'s ongoing clinical study in Europe, pharmacology of MP101 and future plans. Very much looking forward to going back to my old stomping grounds when I was 22, Chicago, my first job (Abbott Labs) after undergrad! Poster # C67, session PSTR015, Oct. 5 from 1-5pm.?Abstract # 1768 #ALS #MS #Alzheimers #Huntingtons #mitochondria #BDNF

For those interested in truly novel pain medicine, at the upcoming Military Health System Research Symposium (MHSRS), Mitochon Pharmaceuticals, Inc., in collaboration with renowned chronic neuropathic pain expert Dr. Karin Westlund High, Ph.D., Distinguished Professor (UNM Health Sciences Center), is pleased to debut our research program.?This completely novel mitochondrial specific target approach, non-addictive, non-opioid, with oral uncoupler MP201 in trigeminal neuralgia (TgN) model will showcase the striking results significantly reducing Von Frey scores in one of the most serious pain indications, considered the “suicide disease”. Dr. Westlund’s talk titled “Rescue of Neuropathic Pain by Mitochondrial Uncoupler MP201”, 1pm (1300) Tuesday August 27th at the breakout session: Assuaging Agony: Novel Pain Therapeutics. Abstract # MHSRS-24-10993. Kissimmee Florida https://www.mhsrs.net/ #TgN #neuropathic #pain #mitochondria #neuralgia #military

Happy to share news that EMA has approved our Phase 2a trial to begin in Q1. We are looking forward to showing MP101's activity in these devastating nuerodegenerative diseases! https://lnkd.in/gby22PVj